These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1535375)

  • 1. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine.
    Bacchetti P; Moss AR; Andrews JC; Jacobson MA
    J Acquir Immune Defic Syndr (1988); 1992; 5(7):732-6. PubMed ID: 1535375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Gazzard B
    AIDS; 1993 Oct; 7(10):959-67. PubMed ID: 7903542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
    Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
    Choi S; Lagakos SW; Schooley RT; Volberding PA
    Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time.
    Graham NM; Piantadosi S; Park LP; Phair JP; Rinaldo CR; Fahey JL
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1258-66. PubMed ID: 7901384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group.
    BMJ; 1992 Jan; 304(6818):13-7. PubMed ID: 1346505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.
    Yarchoan R; Venzon DJ; Pluda JM; Lietzau J; Wyvill KM; Tsiatis AA; Steinberg SM; Broder S
    Ann Intern Med; 1991 Aug; 115(3):184-9. PubMed ID: 1676252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group.
    McKinney RE; Wilfert C
    J Pediatr; 1994 Nov; 125(5 Pt 1):728-33. PubMed ID: 7965424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
    Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R
    AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
    Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
    Scand J Infect Dis; 1992; 24(5):563-5. PubMed ID: 1361240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials.
    Lin DY; Fischl MA; Schoenfeld DA
    Stat Med; 1993 May; 12(9):835-42. PubMed ID: 8101011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.